Skip to main content
Premium Trial:

Request an Annual Quote

Horizon CombinatoRx to Profile Oncology Asset for Pharma Firm

NEW YORK(GenomeWeb) – Horizon Discovery today said that its CombinatoRx division has inked a contract with an unnamed "top 10" pharmaceutical firm to profile a lead oncology asset. 

Horizon CombinatoRx will be paid $750,000 for work completed within a five-month period, it said. The company provides its partners access to the combination high-throughput screening platform and Chalice analytics software for the screening and analysis of thousands of complementary drug combinations. Horizon acquired CombinatoRx in June for $8 million.

Last month, Horizon CombinatoRx announced a similar contract with another undisclosed pharma firm. In July, it signed a contract with Otsuka Pharmaceutical Development and Commercialization to perform in vitro cell line screening of certain OPDC candidates in development. 

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.